LOS ANGELES, Feb. 29, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against iRhythm Technologies, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC).
Class Period: January 11, 2022 – May 30, 2023
Lead Plaintiff Deadline: April 8, 2024
If you wish to serve as lead plaintiff of the iRhythm lawsuit, you can submit your contact information at www.glancylaw.com/cases/iRhythm-Technologies-Inc-1/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) iRhythm failed to comply with the FDA’s marketing regulations and prohibitions against the promotion of products for uncleared and unapproved uses contrary to the representations it made to investors; (2) iRhythm failed to report adverse events to the FDA in violation of the reporting requirements of Medical Device Reporting regulations; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Follow us for updates on LinkedIn, Twitter, or Facebook.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
SOURCE Glancy Prongay & Murray LLP
